Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Indeed, record-breaking vaccine development played a big role in keeping the SARS-CoV-2 virus at bay. Vaccine skeptics have ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

The Florida surgeon general in January called for a halt in the use of covid mRNA vaccines. And in Texas, Attorney General ...

The S&P 500 advanced 1.1% on Wednesday, March 5, as the White House announced it would delay tariffs affecting U.S.

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Freshfields has won a Düsseldorf regional court patent dispute on behalf of client Moderna against German COVID-19 vaccine ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Researchers racing to develop bird flu vaccines for humans have turned to a cutting-edge technology that enabled the rapid development of lifesaving covid shots.

Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...